Trials / Recruiting
RecruitingNCT05009797
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 750 (estimated)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | atrial fibrillation catheter ablation | The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician. |
Timeline
- Start date
- 2023-02-16
- Primary completion
- 2031-02-01
- Completion
- 2031-02-01
- First posted
- 2021-08-18
- Last updated
- 2026-04-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05009797. Inclusion in this directory is not an endorsement.